BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33593827)

  • 1. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
    Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
    Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
    Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
    Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
    Isgrò MA; Vitale MG; Celentano E; Nocerino F; Porciello G; Curvietto M; Mallardo D; Montagnese C; Russo L; Zanaletti N; Avallone A; Pensabene M; De Laurentiis M; Centonze S; Pignata S; Cannella L; Morabito A; Caponigro F; Botti G; Masucci GV; Giannarelli D; Cavalcanti E; Ascierto PA
    J Transl Med; 2021 Mar; 19(1):132. PubMed ID: 33789686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
    Yang Y; Xu G
    Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
    Yatim N; Boussier J; Tetu P; Smith N; Bruel T; Charbit B; Barnabei L; Corneau A; Da Meda L; Allayous C; Baroudjian B; Jebali M; Herms F; Grzelak L; Staropoli I; Calmettes V; Hadjadj J; Peyrony O; Cassius C; LeGoff J; Kramkimel N; Aractingi S; Fontes M; Blanc C; Rieux-Laucat F; Schwartz O; Terrier B; Duffy D; Lebbé C
    Sci Adv; 2021 Aug; 7(34):. PubMed ID: 34407944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature.
    Pala L; Conforti F; Cocorocchio E; Ferrucci P; De Pas MT; Stucchi S; Repetto M; Saponara M; Queirolo P
    Cancer Invest; 2021 Jan; 39(1):9-14. PubMed ID: 33125301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic.
    Zambelli A; Chiudinelli L; Fotia V; Negrini G; Bosetti T; Callegaro A; Di Croce A; Caremoli ER; Moro C; Milesi L; Poletti P; Tasca C; Mandalà M; Merelli B; Mosconi S; Arnoldi E; Bettini A; Bonomi L; Messina C; Ghilardi L; Chirco A; Maracino M; Tondini C
    Oncologist; 2021 Apr; 26(4):341-347. PubMed ID: 33355953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.
    van Marcke C; Honoré N; van der Elst A; Beyaert S; Derouane F; Dumont C; Aboubakar Nana F; Baurain JF; Borbath I; Collard P; Cornélis F; De Cuyper A; Duhoux FP; Filleul B; Galot R; Gizzi M; Mazzeo F; Pieters T; Seront E; Sinapi I; Van den Eynde M; Whenham N; Yombi JC; Scohy A; van Maanen A; Machiels JP
    BMC Cancer; 2021 May; 21(1):578. PubMed ID: 34016086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
    Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
    J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
    Cortellini A; Dettorre GM; Dafni U; Aguilar-Company J; Castelo-Branco L; Lambertini M; Gennatas S; Angelis V; Sita-Lumsden A; Rogado J; Pedrazzoli P; Viñal D; Prat A; Rossi M; Berardi R; Alonso-Gordoa T; Grisanti S; Dimopoulou G; Queirolo P; Pradervand S; Bertuzzi A; Bower M; Arnold D; Salazar R; Tucci M; Harrington KJ; Mazzoni F; Mukherjee U; Tsourti Z; Michielin O; Pommeret F; Brunet J; Vincenzi B; Tonini G; Patriarca A; Biello F; Krengli M; Tabernero J; Pentheroudakis G; Gennari A; Peters S; Romano E; Pinato DJ
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Klebanov N; Pahalyants V; Murphy WS; Theodosakis N; Zubiri L; Klevens RM; Kwatra SG; Lilly E; Reynolds KL; Semenov YR
    Oncologist; 2021 May; 26(5):e898-e901. PubMed ID: 33783099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.
    Tagliamento M; Spagnolo F; Poggio F; Soldato D; Conte B; Ruelle T; Barisione E; De Maria A; Del Mastro L; Di Maio M; Lambertini M
    Eur J Clin Invest; 2020 Sep; 50(9):e13315. PubMed ID: 32535890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
    Abid MB
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19.
    Pala L; Conforti F; Saponara M; De Pas T; Giugliano F; Omodeo Salè E; Jemos C; Rubatto M; Agostini A; Quaglino P; Fava P; Fierro MT; Queirolo P
    Semin Oncol; 2020 Oct; 47(5):302-304. PubMed ID: 32883537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.